Roche Pharmaceutical Development and Sales Overview

Esbriet CER growth -34% Europe -1% Global sales CHFbn CER growth -25% Regional sales US 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0 YTD Sep 19 YTD Sep 20 YTD Sep 21 YTD Sep 22 YTD Sep 2022 sales of CHF 590m • US: Generics have entered the market in Q2, rapid erosion expected • EU: Generic entry expected in Q4 CER-Constant Exchange Rates International -22% Roche 166

View entire presentation